SLDB Q4 2022 Earnings — Solid Biosciences Inc. Revenue & Financial Results | Market Cap Arena

SLDBSolid Biosciences Inc.

$644M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$35M

Net Income

-$15M

EPS (Diluted)

$-1.89

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$35M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$260M

Total Liabilities

$49M

Stockholders' Equity

$212M

Cash & Equivalents

$155M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$3M	-100.0%
Gross Profit	$0	$3M	-100.0%
Operating Income	-$35M	-$19M	-85.3%
Net Income	-$15M	-$19M	+18.6%